Division of Bone Marrow Transplantation and Immune Deficiency, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.
Biol Blood Marrow Transplant. 2013 Nov;19(11):1546-56. doi: 10.1016/j.bbmt.2013.07.017. Epub 2013 Jul 23.
Pulmonary hypertension (PH) is a potentially fatal complication of hematopoietic stem cell transplantation (HSCT). Given its nonspecific clinical presentation, it is likely that this clinical entity is underdiagnosed after HSCT. Data describing the incidence, risk factors, and etiology of PH in HSCT recipients are minimal. Physicians caring for HSCT recipients should be aware of this severe post-transplant complication because timely diagnosis and treatment may allow improved clinical outcomes. We summarize the pathophysiology, clinical presentation, diagnosis, and management of PH in HSCT recipients.
肺高血压（PH）是造血干细胞移植（HSCT）的一种潜在致命并发症。鉴于其非特异性临床表现，HSCT 后该临床病症很可能被漏诊。描述 HSCT 受者 PH 的发生率、危险因素和病因的数据很少。治疗 HSCT 受者的医生应该了解这种严重的移植后并发症，因为及时的诊断和治疗可能会改善临床结果。我们总结了 HSCT 受者 PH 的病理生理学、临床表现、诊断和治疗。
